JP2023519100A5 - - Google Patents
Info
- Publication number
- JP2023519100A5 JP2023519100A5 JP2022548596A JP2022548596A JP2023519100A5 JP 2023519100 A5 JP2023519100 A5 JP 2023519100A5 JP 2022548596 A JP2022548596 A JP 2022548596A JP 2022548596 A JP2022548596 A JP 2022548596A JP 2023519100 A5 JP2023519100 A5 JP 2023519100A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- group
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975047P | 2020-02-11 | 2020-02-11 | |
| US62/975,047 | 2020-02-11 | ||
| US202063030131P | 2020-05-26 | 2020-05-26 | |
| US63/030,131 | 2020-05-26 | ||
| PCT/US2021/017427 WO2021163170A1 (en) | 2020-02-11 | 2021-02-10 | Anti-acvr1 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519100A JP2023519100A (ja) | 2023-05-10 |
| JP2023519100A5 true JP2023519100A5 (enExample) | 2024-02-22 |
Family
ID=74860418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548596A Pending JP2023519100A (ja) | 2020-02-11 | 2021-02-10 | 抗ａｃｖｒ１抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11945872B2 (enExample) |
| EP (1) | EP4103617A1 (enExample) |
| JP (1) | JP2023519100A (enExample) |
| KR (1) | KR20220140802A (enExample) |
| CN (1) | CN115362175A (enExample) |
| AU (1) | AU2021218675A1 (enExample) |
| CA (1) | CA3167441A1 (enExample) |
| IL (1) | IL295419A (enExample) |
| MX (1) | MX2022009769A (enExample) |
| WO (1) | WO2021163170A1 (enExample) |
| ZA (1) | ZA202208222B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113366019B (zh) | 2018-10-23 | 2024-08-27 | 科乐斯疗法公司 | Alk2抗体及其使用方法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| TW202328190A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商來凱醫藥科技（上海）有限公司 | 抗acvr2a抗體及其用途 |
| WO2024092133A1 (en) | 2022-10-27 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CA2649770C (en) | 2006-04-18 | 2017-08-15 | The Trustees Of The University Of Pennsylvania | Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop) |
| US8859752B2 (en) | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| JP5642972B2 (ja) * | 2007-02-21 | 2014-12-17 | ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| TWI703156B (zh) * | 2015-01-30 | 2020-09-01 | 學校法人埼玉醫科大學 | 抗ａｌｋ２抗體 |
| MX2020008582A (es) | 2018-03-05 | 2020-09-21 | Univ Saitama Medical | Composicion farmaceutica para tratar o prevenir la osificacion heterotopica. |
| AU2019310590A1 (en) * | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| CN113366019B (zh) | 2018-10-23 | 2024-08-27 | 科乐斯疗法公司 | Alk2抗体及其使用方法 |
| WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| EP4008350A4 (en) | 2019-07-26 | 2023-06-14 | Saitama Medical University | ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1 |
-
2021
- 2021-02-10 KR KR1020227031475A patent/KR20220140802A/ko active Pending
- 2021-02-10 US US17/172,856 patent/US11945872B2/en active Active
- 2021-02-10 EP EP21710676.4A patent/EP4103617A1/en active Pending
- 2021-02-10 IL IL295419A patent/IL295419A/en unknown
- 2021-02-10 CN CN202180027355.8A patent/CN115362175A/zh active Pending
- 2021-02-10 MX MX2022009769A patent/MX2022009769A/es unknown
- 2021-02-10 WO PCT/US2021/017427 patent/WO2021163170A1/en not_active Ceased
- 2021-02-10 AU AU2021218675A patent/AU2021218675A1/en active Pending
- 2021-02-10 JP JP2022548596A patent/JP2023519100A/ja active Pending
- 2021-02-10 CA CA3167441A patent/CA3167441A1/en active Pending
-
2022
- 2022-07-22 ZA ZA2022/08222A patent/ZA202208222B/en unknown
-
2024
- 2024-02-22 US US18/584,551 patent/US20240190974A1/en active Pending